Logo image of CRNA.OL

CIRCIO HOLDING (CRNA.OL) Stock Fundamental Analysis

OSL:CRNA - Euronext Oslo - NO0013033795 - Common Stock - Currency: NOK

0.639  +0.02 (+2.73%)

Fundamental Rating

2

CRNA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 73 industry peers in the Biotechnology industry. Both the profitability and financial health of CRNA have multiple concerns. CRNA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CRNA had positive earnings in the past year.
CRNA had a negative operating cash flow in the past year.
In the past 5 years CRNA reported 4 times negative net income.
In the past 5 years CRNA always reported negative operating cash flow.
CRNA.OL Yearly Net Income VS EBIT VS OCF VS FCFCRNA.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M -400M

1.2 Ratios

CRNA's Return On Assets of 263.50% is amongst the best of the industry. CRNA outperforms 100.00% of its industry peers.
Industry RankSector Rank
ROA 263.5%
ROE N/A
ROIC N/A
ROA(3y)-202.31%
ROA(5y)-129%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CRNA.OL Yearly ROA, ROE, ROICCRNA.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRNA.OL Yearly Profit, Operating, Gross MarginsCRNA.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100K -200K -300K -400K

More info and screens

1

2. Health

2.1 Basic Checks

CRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CRNA has more shares outstanding
CRNA has less shares outstanding than it did 5 years ago.
CRNA has a better debt/assets ratio than last year.
CRNA.OL Yearly Shares OutstandingCRNA.OL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
CRNA.OL Yearly Total Debt VS Total AssetsCRNA.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

CRNA has an Altman-Z score of -9.59. This is a bad value and indicates that CRNA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -9.59, CRNA is not doing good in the industry: 72.60% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.59
ROIC/WACCN/A
WACC5.54%
CRNA.OL Yearly LT Debt VS Equity VS FCFCRNA.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 0.63 indicates that CRNA may have some problems paying its short term obligations.
The Current ratio of CRNA (0.63) is worse than 80.82% of its industry peers.
A Quick Ratio of 0.63 indicates that CRNA may have some problems paying its short term obligations.
The Quick ratio of CRNA (0.63) is worse than 78.08% of its industry peers.
Industry RankSector Rank
Current Ratio 0.63
Quick Ratio 0.63
CRNA.OL Yearly Current Assets VS Current LiabilitesCRNA.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

CRNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 116.74%, which is quite impressive.
Looking at the last year, CRNA shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)116.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%107.52%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
CRNA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 48.33% yearly.
EPS Next Y-183.35%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-25.6%
Revenue Next 2Y48.33%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
CRNA.OL Yearly Revenue VS EstimatesCRNA.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2022 2023 2024 2025 2026 50M 100M 150M 200M 250M
CRNA.OL Yearly EPS VS EstimatesCRNA.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2023 2024 2025 0 -20 -40 -60

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

CRNA is valuated cheaply with a Price/Earnings ratio of 0.23.
CRNA's Price/Earnings ratio is rather cheap when compared to the industry. CRNA is cheaper than 100.00% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.25. CRNA is valued rather cheaply when compared to this.
CRNA is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 0.23
Fwd PE N/A
CRNA.OL Price Earnings VS Forward Price EarningsCRNA.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRNA.OL Per share dataCRNA.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CRNA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CIRCIO HOLDING

OSL:CRNA (5/30/2025, 7:00:00 PM)

0.639

+0.02 (+2.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-10 2025-04-10/amc
Earnings (Next)08-28 2025-08-28
Inst Owners0.21%
Inst Owner ChangeN/A
Ins Owners9.79%
Ins Owner ChangeN/A
Market Cap60.54M
Analysts85.71
Price Target3.06 (378.87%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 0.23
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)2.79
EY436.62%
EPS(NY)-3.8
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0
BVpS-0.13
TBVpS-0.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 263.5%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-202.31%
ROA(5y)-129%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.63
Quick Ratio 0.63
Altman-Z -9.59
F-Score5
WACC5.54%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)116.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%107.52%
EPS Next Y-183.35%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-25.6%
Revenue Next 2Y48.33%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y57.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-109.26%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y54.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.56%
OCF growth 3YN/A
OCF growth 5YN/A